Spyre Therapeutics, Inc. (SYRE)
80.10
+1.47
(+1.87%)
USD |
NASDAQ |
Oct 15, 16:00
80.15
+0.05
(+0.06%)
After-Hours: 20:00
Spyre Therapeutics Research and Development Expense (Quarterly) : 65.50M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 65.50M |
| March 31, 2026 | 60.41M |
| December 31, 2025 | 44.64M |
| September 30, 2025 | 45.25M |
| June 30, 2025 | 40.14M |
| March 31, 2025 | 41.62M |
| December 31, 2024 | 50.48M |
| September 30, 2024 | 44.74M |
| June 30, 2024 | 32.64M |
| March 31, 2024 | 34.93M |
| December 31, 2023 | 33.68M |
| September 30, 2023 | 24.66M |
| June 30, 2023 | 17.39M |
| March 31, 2023 | 13.78M |
| December 31, 2022 | 14.25M |
| September 30, 2022 | 11.98M |
| June 30, 2022 | 15.37M |
| March 31, 2022 | 16.98M |
| December 31, 2021 | 16.78M |
| September 30, 2021 | 14.85M |
| June 30, 2021 | 13.58M |
| March 31, 2021 | 11.86M |
| December 31, 2020 | 15.76M |
| September 30, 2020 | 12.45M |
| Date | Value |
|---|---|
| June 30, 2020 | 16.87M |
| March 31, 2020 | 14.56M |
| December 31, 2019 | 17.57M |
| September 30, 2019 | 17.84M |
| June 30, 2019 | 14.81M |
| March 31, 2019 | 14.39M |
| December 31, 2018 | 11.80M |
| September 30, 2018 | 8.929M |
| June 30, 2018 | 9.122M |
| March 31, 2018 | 6.87M |
| December 31, 2017 | 5.791M |
| September 30, 2017 | 6.239M |
| June 30, 2017 | 5.835M |
| March 31, 2017 | 4.949M |
| December 31, 2016 | 4.741M |
| September 30, 2016 | 5.385M |
| June 30, 2016 | 4.42M |
| March 31, 2016 | 3.596M |
| December 31, 2015 | 3.966M |
| September 30, 2015 | 3.129M |
| June 30, 2015 | 2.736M |
| March 31, 2015 | 1.622M |
| December 31, 2014 | 2.553M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| AbbVie, Inc. | 2.344B |
| Incyte Corp. | 497.47M |
| SELLAS Life Sciences Group, Inc. | 6.272M |
| Relay Therapeutics, Inc. | 76.48M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |